Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)

Affiliation auteurs!!!! Error affiliation !!!!
TitrePlasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)
Type de publicationJournal Article
Year of Publication2015
AuteursCortes J, Vrdoljak E, Puglisi F, Marschner N, Gligorov J, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, Veyret C, Fontana A, Oestergaard M, de Ducla S, Freudensprung U, von Minckwitz G
JournalCANCER RESEARCH
Volume75
Date PublishedMAY 1
Type of ArticleMeeting Abstract
ISSN0008-5472
DOI10.1158/1538-7445.SABCS14-P3-06-08